AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 04:41:02 2024-05-22 am EDT 5-day change 1st Jan Change
12,361 GBX -0.02% Intraday chart for AstraZeneca PLC +1.48% +16.54%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ASTRAZENECA : Gets a Neutral rating from Deutsche Bank ZD
AstraZeneca to present new oncology data CF
ASTRAZENECA : JP Morgan keeps its Buy rating ZD
US Equity Indexes Little Changed as Fed Officials Pepper Views on Policy Path, Investors Brace for Nvdia's Earnings MT
US Equity Indexes Slightly Higher in Midday Trading MT
European Equities Close Lower in Tuesday Trading; AstraZeneca Targets $80 Billion in Revenue by 2030 MT
London dips as eyes turn to UK inflation reading AN
London's FTSE 100 closes at one week-low ahead of CPI data RE
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET DJ
AstraZeneca says building China supply chain amid US-China tensions RE
AstraZeneca aims for $80 bln in total revenue by 2030 RE
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET DJ
Stocks fall but pound up as IMF ups UK forecast AN
Stocks fall but pound up as IMF ups UK forecast AN
London stocks open lower amid Fed's cautious stance Our Logo
ASTRAZENECA : Receives a Sell rating from UBS ZD
AstraZeneca Targets $80 Billion Revenue by 2030, Expects to Launch 20 New Medicines MT
FTSE 100 declines after Asian stocks fall AN
AstraZeneca aims to deliver $80 billion in total revenue by 2030 RE
AstraZeneca aims to almost double sales by 2030 CF
AstraZeneca eyes new era of growth with bold new revenue aim AN
London stocks slip as Fed's cautious stance weighs on sentiment RE
AstraZeneca Targets $80 Billion Revenue by 2030 MT
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2 USD
Average target price
168.3 USD
Spread / Average Target
+7.05%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. Adherium’s Hailie Smartinhaler Secures FDA Approval for Use with AstraZeneca's Airsupra and Breztri Inhalation Devices
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW